Climb Bio (NASDAQ:CLYM) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Climb Bio (NASDAQ:CLYM) in a report issued on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $10.00 price target on the stock.

Climb Bio Stock Up 0.9 %

Climb Bio stock opened at $3.26 on Monday. The company has a market capitalization of $219.15 million, a P/E ratio of -1.53 and a beta of -0.34. Climb Bio has a 1-year low of $2.35 and a 1-year high of $11.55.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.